goeckerman regimen
Recently Published Documents


TOTAL DOCUMENTS

23
(FIVE YEARS 1)

H-INDEX

11
(FIVE YEARS 0)

2021 ◽  
Vol 5 (5) ◽  
pp. 554-558
Author(s):  
Nicholas Brownstone ◽  
Daniel Cummins ◽  
Jocelyn Gandelman ◽  
Tina Bhutani ◽  
Wilson Liao

The development of immune checkpoint inhibitors has been a major breakthrough in cancer therapy. Here, we report the effective use of the Goeckerman regimen in the treatment of an evolving immune checkpoint inhibitor dermatosis. The patient is a 67-year-old male who was diagnosed with mesothelioma in April 2015 and was started on pembrolizumab presenting with subsequent skin eruptions (psoriasiform dermatitis and bullous disease). He received eight months of Goeckerman therapy at University of California, San Francisco, Psoriasis and Skin Treatment Center. Within days of starting Goeckerman therapy, he had rapid improvement in his skin lesions along with a reduction in pruritus. The Goeckerman regimen is further discussed as a novel treatment method for checkpoint inhibitor dermatoses.


2016 ◽  
Vol 75 (5) ◽  
pp. 1068-1071 ◽  
Author(s):  
Benjamin Farahnik ◽  
Kourosh Beroukhim ◽  
Melissa Danesh ◽  
Mio Nakamura ◽  
Michael Abrouk ◽  
...  

2015 ◽  
Vol 72 (1) ◽  
pp. e40-e42 ◽  
Author(s):  
Eric Sorenson ◽  
Ethan Levin ◽  
John Koo ◽  
Timothy G. Berger

2014 ◽  
Vol 115 (04) ◽  
pp. 229-232 ◽  
Author(s):  
D. Ranna ◽  
C. Andrys ◽  
J. Krejsek ◽  
K. Hamakova ◽  
J. Kremlacek ◽  
...  

Author(s):  
Rishu Gupta ◽  
Maya Debbaneh ◽  
Daniel Butler ◽  
Monica Huynh ◽  
Ethan Levin ◽  
...  

2009 ◽  
Vol 34 (8) ◽  
pp. e881-e883 ◽  
Author(s):  
L. Borska ◽  
C. Andrys ◽  
J. Krejsek ◽  
K. Hamakova ◽  
J. Kremlacek ◽  
...  

2009 ◽  
Vol 26 (1) ◽  
pp. 23-27 ◽  
Author(s):  
Lenka Borska ◽  
Ctirad Andrys ◽  
Jan Krejsek ◽  
Kvetoslava Hamakova ◽  
Jan Kremlacek ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document